The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.
about
Biological markers of amyloid beta-related mechanisms in Alzheimer's diseaseTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsAlzheimer's therapeutics: translation of preclinical science to clinical drug developmentA Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-SecretaseBMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease modelsLowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.Inhibitors of signal peptide peptidase (SPP) affect HSV-1 infectivity in vitro and in vivo.Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice.Transgenic models of Alzheimer's disease: learning from animalsN-{N-[2-(3,5-Difluorophenyl)acetyl]-(S)-alanyl}-(S)-phenylglycine tert-butyl ester (DAPT): an inhibitor of γ-secretase, revealing fine electronic and hydrogen-bonding features.Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa.Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species.Reduction of β-amyloid deposits by γ-secretase inhibitor is associated with the attenuation of secondary damage in the ipsilateral thalamus and sensory functional improvement after focal cortical infarction in hypertensive rats.Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner.A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.Drug development for Alzheimer's disease: recent progressInhibition of Notch1 signaling reduces abdominal aortic aneurysm in mice by attenuating macrophage-mediated inflammation.New prospects and strategies for drug target discovery in neurodegenerative disordersIn Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side EffectsGamma-secretase inhibition and modulation for Alzheimer's disease.Inhibition and modulation of gamma-secretase for Alzheimer's diseaseReduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model.Magnetic resonance imaging for monitoring therapeutic response in a transgenic mouse model of Alzheimer's disease using voxel-based analysis of amyloid plaques.The structure and function of Alzheimer's gamma secretase enzyme complex.Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo.APP substitutions V715F and L720P alter PS1 conformation and differentially affect Abeta and AICD generation.Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearanceChronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures.Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.The crosstalk between transforming growth factor-β1 and delta like-1 mediates early chondrogenesis during embryonic endochondral ossification.Substituted thiazolamide coupled to a redox delivery system: a new gamma-secretase inhibitor with enhanced pharmacokinetic profile.Effects of amyloid-beta peptides on hydrogen peroxide-metabolizing enzymes in rat brain in vivo.In vitro characterization of a gamma-secretase radiotracer in mammalian brain.
P2860
Q24622136-6EFFF0E4-A2B0-4A65-B655-0D5F78865967Q26822002-434C933A-D431-4C68-83F8-B318A9D14892Q26829267-DD8EBF97-ECAE-4BBA-925F-DAAEDED3CA39Q27684122-57438E04-764F-4CC3-BE00-A6C1E774C549Q28829902-AB8211C5-F412-4533-A82B-AAAF52BB146DQ33598454-2ED9BD58-B5F5-4F7D-B2AF-7E4F65D5E326Q33717645-94EA6511-B18A-48A9-9B19-7DC874E40B9AQ33797754-4A0FA88A-E2B5-4417-A84D-C7D4C5943072Q33844718-38AED441-B3F4-4452-A36C-A58FDBBDC721Q34457604-41C52E3C-F435-46C0-AFF9-E451A77599E1Q34498158-DED1CEDF-CD53-47B1-A86D-98AF3673B067Q34543713-432183E3-A07F-450F-9BDE-6FC813797024Q34624507-29792BF4-9AE9-42AF-92F8-6ADDC02048BAQ34627610-FD5DFFD0-C93A-4436-81EF-01CD455B651BQ34656871-ADAD7478-8D03-46AD-AE30-D97BE03257F6Q34725167-27718E77-4788-4544-B2F4-964F209B6AFAQ35103136-D5804C36-73DA-447C-8991-EAD6AC5E1DEDQ35545974-89B7C2F5-7866-4027-96D2-9F08A1958A57Q35741317-BA0D0FB0-9BEB-4E27-A726-76A70C49A215Q36401411-9CCDDDF1-6252-4C52-8242-69BD45C2F4D3Q36729084-8EDC658D-06EE-4894-986E-8DD9D70232CDQ37130650-17ABA5BB-FBEF-458F-9B96-25D1B816A89AQ37215842-2FBC4040-CE5D-4B8B-B9C0-53F7D2C571B0Q37272217-958D799E-7077-4FB1-B0D0-917C8694D744Q37585625-61F55213-BCC0-44FB-B82D-F77BEE0223A3Q37643736-94AD9642-FE37-4EC0-9D4B-31F9EA452AB5Q37773826-536CD1A4-8E86-48A7-9A07-948C363F565AQ37855656-2F11C739-90E5-479D-984B-134DD8A1D888Q37979824-51738212-A756-4858-85E5-4006C54A3015Q40375910-596F5153-CE5F-4490-B3B3-37E4A0E48DBCQ40387366-C2432D58-B251-4F59-9D3B-7FDE5FAC1DB0Q40601680-EC89B880-D57C-4E8D-A8A9-C5EE4B493639Q41989700-43C8B8EC-2B56-4401-81A8-4A5DBE56A8E0Q42044617-7B3F3C5B-4998-47D1-9321-A5E5E0E88D93Q42753532-5356E307-907E-44A0-9E00-390F97CB0071Q44460129-5C18E155-B46C-431F-A588-E47E961A28F4Q44609743-4E8E55A8-A43D-41A0-96EF-9A2B9F5BA28EQ45259689-8A507AFC-8586-4747-BD2B-2E7CF7726322Q46527840-679C0E6E-47FB-4530-9301-191FD5672EFCQ46814160-9AC9A4C4-9B5D-4884-89B9-86619831D204
P2860
The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@en
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@nl
type
label
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@en
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@nl
prefLabel
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@en
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@nl
P2093
P356
P1476
The gamma-secretase inhibitor ...... (plaque-bearing) Tg2576 mice.
@en
P2093
Carol S Himes
Giovanni Pallante
Kalpana M Merchant
Lisa Adams
Shinji Yamazaki
P304
P356
10.1124/JPET.102.048280
P407
P577
2003-03-06T00:00:00Z